Compare Snowflake Inc (SNOW) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Snowflake (SNOW) trades at $357.76, down 0.72% today, with strong technical momentum showing bullish moving averages and support at $355. The company demonstrates robust revenue growth, reaching $3.63 billion in 2025, though it remains unprofitable with a -20.07% net margin. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive with 81% buy ratings and a $418.03 consensus target.

The outlook remains constructive given strong revenue growth and strategic partnerships, but investors face risks from continued losses, high valuation multiples (P/S 22.66), and potential dilution from the recent $3.75 billion convertible note offering. The stock offers growth exposure but requires tolerance for current profitability challenges.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.